Kolexia
Kolb-Bigorgne Brigitte Médecine interne
Kolb-Bigorgne Brigitte
Médecine interne
Hôpital Robert-Debré Reims
Reims, France
109 Activités
117 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Récidive tumorale locale Translocation génétique Insuffisance rénale Aberrations des chromosomes Délétion de segment de chromosome Lymphomes Neutropénie

Collaborateurs

Voir plus
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France
Roussel Murielle
Roussel Murielle
Hôpital Dupuytren, Limoges, France

Industries

Voir plus
IQVIA
33 collaboration(s)
Dernière en 2020
A+A
30 collaboration(s)
Dernière en 2020
M3 Global Research Ltd
20 collaboration(s)
Dernière en 2020
B3TSI
9 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Essai Clinique (Takeda Pharmaceutical)   07 février 2023
IFM2014-02: IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
Essai Clinique (Janssen)   17 mai 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood   09 mai 2022
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.
Leukemia   14 octobre 2021
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
Haematologica   01 août 2021
Cassiopeia: Study of Daratumumab in Combination With Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects With Newly Diagnosed Multiple Myeloma
Essai Clinique (Intergroupe Francophone du Myélome)   03 décembre 2020
BVD: A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (>= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy
Essai Clinique (Intergroupe Francophone du Myélome)   03 décembre 2020
Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03)
Blood   13 novembre 2019
Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey
Blood   13 novembre 2019
FIRST: A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation.
Essai Clinique (Celgene)   07 novembre 2019